A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies (CD20/19 CAR T)
An Open-Label, Non-Randomized, Phase I, Prospective, Dose- Finding Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
Sponsor: GenomeFrontier Therapeutics TW Co., Ltd.
Listed as NCT06703892, this PHASE1 trial focuses on Diffuse Large B Cell Lymphoma Refractory and Diffuse Large B Cell Lymphoma Relapsed and remains actively recruiting participants. Sponsored by GenomeFrontier Therapeutics TW Co., Ltd., it has been updated 5 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
5 versions recorded-
Jan 2026 — Present [monthly]
Recruiting PHASE1
-
Jul 2025 — Jan 2026 [monthly]
Recruiting PHASE1
-
May 2025 — Jul 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2025 — May 2025 [monthly]
Not Yet Recruiting PHASE1
-
Dec 2024 — Feb 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GenomeFrontier Therapeutics TW Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .